A Proposal for Integrated Efficacy-to-effectiveness (E2E) Clinical Trials

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2013 Sep 25

PMID 24060819

Citations 15

Authors

H P Selker

K A Oye

H-G Eichler

N L Stockbridge

C R Mehta

K I Kaitin

N E McElwee

P K Honig

J K Erban

R B DAgostino

Affiliations

Soon will be listed here.

Abstract

We propose an "efficacy-to-effectiveness" (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster incorporation of effectiveness information into regulatory processes.

Citing Articles

Real World Data in Health Technology Assessment of Complex Health Technologies.

Hogervorst M, Ponten J, Vreman R, Mantel-Teeuwisse A, Goettsch W Front Pharmacol. 2022; 13:837302.

PMID: 35222045 PMC: 8866967. DOI: 10.3389/fphar.2022.837302.

Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.

Dagenais S, Russo L, Madsen A, Webster J, Becnel L Clin Pharmacol Ther. 2021; 111(1):77-89.

PMID: 34839524 PMC: 9299990. DOI: 10.1002/cpt.2480.

A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network.

Bernard G, Harris P, Pulley J, Benjamin D, Michael J, Ford D J Clin Transl Sci. 2019; 2(4):187-192.

PMID: 31011433 PMC: 6474372. DOI: 10.1017/cts.2018.319.

Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes.

Klonoff D, Gutierrez A, Fleming A, Kerr D J Diabetes Sci Technol. 2019; 13(6):995-1000.

PMID: 30943790 PMC: 6835188. DOI: 10.1177/1932296819839996.

Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Selker H, Eichler H, Stockbridge N, McElwee N, Dere W, Cohen T Clin Pharmacol Ther. 2019; 105(4):857-866.

PMID: 30610746 PMC: 6422692. DOI: 10.1002/cpt.1347.

References

Kent D, Hayward R . Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007; 298(10):1209-12. DOI: 10.1001/jama.298.10.1209. View

Savvides P, Terrin N, Erban J, Selker H . Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Support Care Cancer. 2003; 11(5):313-20. DOI: 10.1007/s00520-003-0442-z. View

Selker H, Beshansky J, Griffith J . Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern Med. 2002; 137(2):87-95. DOI: 10.7326/0003-4819-137-2-200207160-00006. View

Zijlstra F, de Boer M, Hoorntje J, Reiffers S, Reiber J, Suryapranata H . A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993; 328(10):680-4. DOI: 10.1056/NEJM199303113281002. View

Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J . Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009; 27(18):2962-9. PMC: 2701645. DOI: 10.1200/JCO.2008.19.7939. View

Hassett M, OMalley A, Pakes J, Newhouse J, Earle C . Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006; 98(16):1108-17. DOI: 10.1093/jnci/djj305. View

Mehta C, Gao P, Bhatt D, Harrington R, Skerjanec S, Ware J . Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009; 119(4):597-605. DOI: 10.1161/CIRCULATIONAHA.108.809707. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

Aversano T, Aversano L, Passamani E, Knatterud G, Terrin M, Williams D . Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002; 287(15):1943-51. DOI: 10.1001/jama.287.15.1943. View

10.

Kent D, Vijan S, Hayward R, Griffith J, Beshansky J, Selker H . Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol. 2004; 57(8):843-52. DOI: 10.1016/j.jclinepi.2004.01.008. View

11.

Paik S, Kim C, Wolmark N . HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008; 358(13):1409-11. DOI: 10.1056/NEJMc0801440. View

12.

Eichler H, Oye K, Baird L, Abadie E, Brown J, Drum C . Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012; 91(3):426-37. DOI: 10.1038/clpt.2011.345. View

13.

Kent D, Ruthazer R, Griffith J, Beshansky J, Grines C, Aversano T . Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty for acute myocardial infarction. Am J Cardiol. 2007; 99(10):1384-8. DOI: 10.1016/j.amjcard.2006.12.068. View

14.

Kent D, Selker H, Ruthazer R, Bluhmki E, Hacke W . The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006; 37(12):2957-62. DOI: 10.1161/01.STR.0000249054.96644.c6. View

15.

Selker H, Griffith J, Beshansky J, Schmid C, Califf R, DAgostino R . Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997; 127(7):538-56. DOI: 10.7326/0003-4819-127-7-199710010-00006. View

16.

Mollerup J, Henriksen U, Muller S, Schonau A . Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization. BMC Clin Pathol. 2012; 12:3. PMC: 3305592. DOI: 10.1186/1472-6890-12-3. View

17.

Thorpe K, Zwarenstein M, Oxman A, Treweek S, Furberg C, Altman D . A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009; 62(5):464-75. DOI: 10.1016/j.jclinepi.2008.12.011. View

18.

Kent D, Rothwell P, Ioannidis J, Altman D, Hayward R . Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010; 11:85. PMC: 2928211. DOI: 10.1186/1745-6215-11-85. View

19.

Grines C, Browne K, Marco J, Rothbaum D, Stone G, Okeefe J . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993; 328(10):673-9. DOI: 10.1056/NEJM199303113281001. View

20.

. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997; 336(23):1621-8. DOI: 10.1056/NEJM199706053362301. View